Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151216 · ClinicalTrials.gov registry record · Phase 1
Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00151216 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 10 participants.
The verdict
NCT00151216, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The aim of this study is to treat the signs and symptoms of late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal inherited disease in the brain. This will be accomplished by using delivery of a gene (method called gene transfer) to administer to the brain an experimental drug called AAV2CUhCLN2, a gene transfer vector.
Interventions
- BIOLOGICAL AAV2CUhCLN2 (3x10^12 particle units)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-06 |
| Est. Completion | 2019-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151216
The ClinicalTrials.gov registry entry for NCT00151216 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AAV2CUhCLN2 (3x10^12 particle units) is the first listed.
NCT00151216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151216 about?
NCT00151216 is a clinical study titled "Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis". The aim of this study is to treat the signs and symptoms of late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal inherited disease in the brain. This will be accomplished by using delivery of a gene (method called gene transfer) to administer to the brain an experimental drug called AAV2CU...
What is the current status of trial NCT00151216?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2004-06. Estimated completion is 2019-06.
What interventions are being tested in trial NCT00151216?
The interventions under investigation include: AAV2CUhCLN2 (3x10^12 particle units) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00151216?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.